Monthly SOM230C for Recurrent or Progressive Meningioma
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to evaluate the effectiveness and safety of SOM230C in
treating recurrent meningiomas. SOM230C is a newly discovered drug that may stop meningioma
cells from growing abnormally. This drug has been used in treatment of other tumors, and
information from those other research studies suggests that SOM230C may help to stop the
growth of meningiomas.
Phase:
Phase 2
Details
Lead Sponsor:
Patrick Y. Wen, MD
Collaborators:
Beth Israel Deaconess Medical Center Brigham and Women's Hospital Cedars-Sinai Medical Center Duke University Massachusetts General Hospital Memorial Sloan Kettering Cancer Center Northwestern University Novartis Wake Forest Baptist Health Wake Forest University Health Sciences